LP Therapeutics Inc — Department of Health and Human Services SBIR Phase II: NCI
LP Therapeutics Inc — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,499,999
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NCI
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
The goal of this project is to develop nanometer scale micelles to deliver high concentration of the chemotherapeutic drug daunorubicin DNR directly into acute myeloid leukemia AML stem cells LSCs and eradicate AML from the very root LSCs are a special group of leukemia cells that are relatively resistant to conventional doses of chemotherapy can regenerate more leukemia cells and cause leukemia recurrence